FDA Review of Peptides Raises Public Health Concerns
The FDA's Pharmacy Compounding Advisory Committee will review seven popular peptides, including BPC-157 and Semax, to assess their eligibility for legal compounding amid concerns over limited human clinical evidence supporting their safety and efficacy. Despite widespread social media promotion for uses such as longevity and recovery, FDA scientists have recommended against approving them due to insufficient data, raising public health concerns about unregulated markets and product contamination. The review highlights the gap between social media hype and scientific validation, emphasizing the risks of unvetted peptide products.
articleDetails.fontSize.sizeحجم النص
تنويه: هذا ملخص تم إنشاؤه بواسطة الذكاء الاصطناعي
comments.heading